|
Oct 1
|
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable
|
|
Sep 5
|
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
Aug 15
|
Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 14
|
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call
|
|
Aug 13
|
Fennec Q2 Loss Stays Constant as Revenue More Than Doubles, Appoints Jeffrey Hackman as CEO
|
|
Aug 13
|
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
|
Jun 25
|
Fennec Announces Results of Annual Meeting
|
|
May 14
|
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) largest shareholders are individual investors who were rewarded as market cap surged US$25m last week
|
|
May 14
|
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
|
|
Apr 9
|
Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%
|
|
Apr 5
|
Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)
|
|
Mar 27
|
Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)
|
|
Mar 26
|
Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)
|
|
Mar 22
|
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call
|
|
Mar 21
|
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
|
|
Mar 19
|
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
|
|
Mar 19
|
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
|
|
Mar 18
|
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
|